Share on LinkedInShare on LinkedIn

ARTICLE · 10 JANUARY 2017

Connecting The Dots: Anticipation Requires More Than Listing Scattered Claim Elements

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

On November 30, 2016, the PTAB issued decisions on the institution of inter partes reviews of U.S. Patent No. 6,667,061 (the '061 patent), which relates to formulations for injectable suspensions...

United StatesIntellectual Property

On November 30, 2016, the PTAB issued decisions on the institution of inter partes reviews of U.S. Patent No. 6,667,061 (the '061 patent), which relates to formulations for injectable suspensions having increased viscosity. The '061 patent is owned by Alkermes Pharma Ireland, Ltd. and Alkermes Controlled Therapeutics, Inc. ("Alkermes"), and is listed in the Orange Book in connection with formulations of risperidone (Janssen Pharmaceuticals, Inc.), naltrexone (Alkermes, Inc.), and synthetic exenatide (AstraZeneca AB). Luye Pharma Group Ltd. ("Luye") filed a pair of petitions challenging all but three of the twenty-three claims in the '061 patent. In the case of IPR2016-01095, the PTAB declined to institute an IPR.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from